CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman,...

CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A.
Hoffman, MD Chief Medical Officer
Clinic to Serve as rEEG(R) 'Center of Excellence' Advancing Performance in
Patient Outcomes, Costs and Convenience

COSTA MESA, Calif., Jan. 15 /PRNewswire-FirstCall/ -- CNS Response, Inc.
(OTC Bulletin Board: CNSO) announced today that it has completed the
previously announced acquisition of Neuro-Therapy Clinic, P.C., a
neuropsychiatric clinic in Denver, Colorado. The Company also announced that
Daniel A. Hoffman, MD has been appointed Chief Medical Officer. Dr. Hoffman, a
neuropsychiatrist with more than 25 years experience, was previously National
Medical Director of Neuro-Therapy Clinic.
Len Brandt, Chairman and CEO of CNS Response, reported, "Our close
relationship with Dr. Hoffman and the Neurotherapy Clinic has already played a
significant role in establishing the value of rEEG(R) guidance in medication
management."
George Carpenter, President of CNS Response, commenting on the future,
said, "We expect Neuro-Therapy Clinic to further define the opportunity to use
technology in general, and rEEG in particular, to vastly improve clinic
performance in patient outcomes, costs, and convenience and to best
communicate this to all -- patient, physician, payer. In this way, the
Neuro-Therapy Clinic is something of a dynamic laboratory discovering how to
integrate technology and be a true center of excellence on all of these
measures. Put to practice, this knowledge presents CNS Response with an
opportunity to further our relationship with other clinics and physicians
using rEEG."
"Dr. Hoffman is a leader and a true partner in the development of rEEG so
we are particularly pleased to have him join our team," Mr. Brandt continued.
"Dr. Hoffman will play a critical role in implementing our strategy for the
validation and commercialization of our core rEEG platform."
Established in 1993, Neuro-Therapy Clinic, P.C. is a center for
highly-advanced testing and treatment of neuropsychiatric problems, including
learning, attentional and behavioral challenges, mild head injuries, as well
as depression, anxiety, bipolar and all other common psychiatric disorders.
Dr. Hoffman served as Medical Director for Neuro-Therapy Clinic from
1993-2007. He also served as National Medical Director for CNS Response from
2004-2007 and has maintained a private practice in neuropsychiatry since 1977.
He served as an Assistant Clinical Professor at the University of Colorado
from 1977 to 1996.
Dr. Hoffman has lectured extensively throughout the country on
leading-edge testing and treatment for Psychiatric Medication Selection and
other brain related topics and has been published in more than 30
peer-reviewed articles. He is on the editorial boards of the Journal of
Neurotherapy, the Journal of Applied Psychophysiology and Self Regulation and
the Journal of Neuropsychiatry and Clinical Neurosciences.
About CNS Response
CNS Response is a life-sciences data company focused on the
commercialization of the first patented commercial system that guides
psychiatrists and other physicians to determine proper treatments for patients
with behavioral (mental or addictive) disorders. This technology allows CNS
Response to create and provide simple reports ("rEEG(R) Reports") that
specifically guide physicians to treatment strategies based on the patient's
own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction
with a normative database and a proprietary clinical (symptomatic) database to
identify the following: (1) medication classes most likely to be needed; and
(2) medications within these classes with the most probable treatment
potential for each patient. Reports are provided to physicians in a
relationship analogous to that of a reference laboratory. Prospective,
retrospective and field studies of treatment-resistant patients have reported
treatment success of 70% or greater in managed care, outpatient psychiatric
and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is
also an aide to pharmaceutical developers, who can use rEEG to (1) stratify
study populations to improve the success of FDA clinical trials; (2) provide
insight on effective therapeutic dosing of investigational drugs; (3) identify
additional indications for psychiatric medications; (4) provide insight into
effective drug combinations; and (5) discover opportunities for decision
analytics and support. In addition to these applications, CNS Response
continues to investigate the use of rEEG analysis for development of
proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act
of 1995
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, as
amended. These statements involve risks and uncertainties as set forth in the
Company's filings with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from any
forward-looking statements made herein.
Contacts:

Investor Relations:
Sara Ephraim
(646) 536-7002
sephraim@theruthgroup.com

Media:
Jason Rando / Jennifer Saunders
(646) 536-7033 / 7011
jrando@theruthgroup.com
jsaunders@theruthgroup.com

SOURCE CNS Response, Inc.

Investor Relations: Sara Ephraim, +1-646-536-7002, sephraim@theruthgroup.com,
or Media: Jason Rando, +1-646-536-7033, jrando@theruthgroup.com, or Jennifer
Saunders, +1-646-536-7011, jsaunders@theruthgroup.com, all of The Ruth Group,
for CNS Response, Inc.